{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
NCT00196417: Phase 4 Interventional Unknown status Heparin-Induced Thrombocytopenia
(2003)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
BLA125408
(2016)
Source URL:
First approved in 2016
Source:
BLA125408
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125254
(2016)
Source URL:
First approved in 2016
Source:
BLA125254
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125408
(2016)
Source URL:
First approved in 2016
Source:
BLA125408
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125254
(2016)
Source URL:
First approved in 2016
Source:
BLA125254
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125408
(2016)
Source URL:
First approved in 2016
Source:
BLA125408
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125408
(2016)
Source URL:
First approved in 2016
Source:
BLA125408
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125408
(2016)
Source URL:
First approved in 2016
Source:
BLA125408
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125254
(2016)
Source URL:
First approved in 2016
Source:
BLA125254
Source URL:
Class:
STRUCTURALLY DIVERSE
